Daily Stock Setups

Frincke Named CEO Of Hollis-Eden Pharmaceuticals

Posted on: Mon, 15 Jun 2009 14:19:00 EDT

Symbols: HEPH

Do you know when to trade HEPH ?

Check for a PowerRating from TradingMarkets

Jun 15, 2009 (FinancialWire via COMTEX) --
HEPH | Quote | Chart | News | PowerRating -- (Comment on this article at http://www.financialwire.net/2009/06/15/frincke-named-ceo-of-hollis-eden-pharmaceuticals/)

June 15, 2009 (FinancialWire) -- Hollis-Eden Pharmaceuticals, Inc.'s (NASDAQ: HEPH | Quote | Chart | News | PowerRating) (Current Market Cap: $15.54 Mil.) board has appointed James M. Frincke as president and CEO of the company. Frincke was also elected to the company's board.

Frincke joined Hollis-Eden as vice president of research and development in 1997, was promoted to EVP in 1999, and to chief scientific officer in 2001. He joined Hollis-Eden from Prolinx, where he served as VP of therapeutics research and development from 1995 to 1997.

San Diego-based Hollis-Eden Pharmaceuticals is developing a series of small molecule compounds that are metabolites or synthetic analogs of endogenous hormones derived by the adrenal glands.

The company's clinical drug development candidates include Triolex, a compound currently in clinical trials for the treatment of type 2 diabetes, ulcerative colitis and rheumatoid arthritis, and Apoptone, a compound in a clinical trial for the treatment of late-stage prostate cancer.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

http://www.financialwire.net

For full details on Hollis-eden Pharmaceut (HEPH) HEPH. Hollis-eden Pharmaceut (HEPH) has Short Term PowerRatings at TradingMarkets. Details on Hollis-eden Pharmaceut (HEPH) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.